Welcome to our dedicated page for Vivos Therapeutics news (Ticker: VVOS), a resource for investors and traders seeking the latest updates and insights on Vivos Therapeutics stock.
Vivos Therapeutics Inc (VVOS) provides innovative solutions for sleep-disordered breathing through its proprietary oral appliance therapy and integrated clinical protocols. This news hub offers investors and healthcare professionals direct access to official announcements, financial disclosures, and progress updates on the company's non-invasive treatment alternatives for obstructive sleep apnea.
Our curated collection features regulatory filings, partnership announcements, clinical trial updates, and technology developments. Users will find timely information about the Vivos System implementation, insurance coverage expansions, and research collaborations within the sleep medicine field.
The page organizes content by key categories including quarterly earnings reports, FDA communications, provider network growth, and peer-reviewed study publications. Each update maintains factual accuracy while highlighting the company's position in the $7 billion sleep apnea treatment market.
Bookmark this page for streamlined tracking of Vivos' progress in commercializing its oral appliance technology and expanding its licensed provider network. Check regularly for new developments in patient outcomes data and healthcare provider adoption rates across North America.
Vivos Therapeutics (NASDAQ: VVOS) has signed a definitive agreement to acquire The Sleep Center of Nevada (SCN), the largest sleep center operator in Nevada, for up to $9 million. The deal includes $6 million in cash, $1.5 million in Vivos common stock at closing, and potential additional $1.5 million in stock tied to performance milestones.
SCN, founded in 2008, serves approximately 3,000 new patients monthly and has generated high seven-figure annual net revenues. The center operates seven locations with nearly 50 beds for overnight sleep testing. About 90% of SCN patients test positive for OSA, with 95% typically referred for CPAP, traditional oral devices, or surgical options.
The acquisition, expected to close in Q2 or Q3 2025, aligns with Vivos' new marketing and distribution model following its June 2024 alliance with Rebis Health. The company aims to expand its FDA-cleared oral appliance treatments for OSA directly to patients seeking alternatives to CPAP or surgery.
Vivos Therapeutics (NASDAQ: VVOS) reported strong financial results for full year 2024, with revenue increasing 9% to $15.0 million from $13.8 million in 2023. Product revenue grew 26% year-over-year, while operating expenses decreased 21% to $20.2 million.
The company maintained a 60% gross margin, with gross profit reaching $9.0 million. Operating loss decreased significantly by 35% to $11.2 million. Cash position stood at $6.3 million after raising $17.9 million through equity transactions in 2024.
Notable achievements include FDA 510(k) clearance for the DNA appliance to treat moderate to severe OSA in children ages 6-17, complementing their 2023 clearance for adult treatment. Patient treatments increased to 58,000 worldwide, up from 42,000 in 2023. The company implemented a strategic pivot towards contractual, profit-sharing alliances with sleep healthcare providers, starting with Rebis Health Holdings, expecting to increase revenue per case by 4-6 times with 50% contribution margins.
Vivos Therapeutics (NASDAQ: VVOS), a medical device and technology company focused on sleep-related breathing disorders treatments, has scheduled its full year 2024 financial results release for Monday, March 31, 2025, after market close.
The company will host a conference call at 5:00 PM ET on the same day to discuss the results and provide updates on recent milestones. Investors can join via phone at (800) 717-1738 (US) or (646) 307-1865 (International). A replay will be available until April 14, 2025, using passcode 1103883. The webcast can be accessed through Vivos' investor relations website, with a 30-day archive available.
Vivos Therapeutics (NASDAQ: VVOS) announced significant expansions and achievements in its strategic alliance with Rebis Health Holdings. The company is extending its FDA-cleared Vivos CARE treatment for OSA into two additional Denver market facilities and plans nationwide expansion through sleep center affiliations and acquisitions.
Initial data shows a 64% acceptance rate for Vivos treatment, with patients preferring it nearly 2:1 over CPAP. The company reports average per case revenue of over $4,700 with gross margins around 70% before profit sharing with Rebis. The new business model shows potential for up to four times greater profit per case compared to their previous distribution model.
The expansion includes new locations in Highlands Ranch and Westminster, expected to be operational by April. Vivos is exploring partnerships with over 2,500 accredited sleep medicine groups nationwide, aiming to accelerate revenue growth and achieve cash flow-positive operations.
Vivos Therapeutics (NASDAQ: VVOS), a medical device and technology company focused on sleep-related breathing disorders, has announced a fireside chat scheduled for February 18, 2025, at 12:00 pm ET. CEO Kirk Huntsman will engage with Water Tower Research's senior analyst Do Kim to discuss several key topics.
The discussion will cover the company's Vivos CARE devices for treating obstructive sleep apnea (OSA) and snoring in adults, as well as moderate to severe OSA in children aged 6-17. Key points to be addressed include the company's strategic shift to a medical-based business model, efforts to establish partnerships with physician-based sleep groups, OSA market dynamics, and the positioning of Vivos CARE devices in OSA treatment.
The event will be listen-only, with a replay available for 30 days in the Investor Relations section of the Vivos website.
Vivos Therapeutics (NASDAQ: VVOS) has announced a $3.5 million registered direct offering priced at-the-market, selling 709,220 shares at $4.935 per share. The company will also issue unregistered short-term warrants in a concurrent private placement to purchase up to 709,220 shares at $4.81 per share, exercisable for two years. If fully exercised, these warrants could generate additional gross proceeds of approximately $3.4 million.
The offering is expected to close around December 24, 2024, with H.C. Wainwright & Co. serving as the exclusive placement agent. Vivos plans to use the net proceeds for working capital and general corporate purposes. The shares are being offered under a shelf registration statement, while the warrants are being issued through a private placement under Section 4(a)(2) of the Securities Act.
Vivos Therapeutics (NASDAQ: VVOS) reported strong Q3 2024 financial results with revenue increasing 17% to $3.9 million compared to Q3 2023. Gross profit reached $2.3 million with margins improving to 60%. Operating expenses decreased by 8%, marking the ninth consecutive quarter of year-over-year reductions. The company achieved significant milestones including FDA clearance for treating moderate to severe OSA in children ages 6-17 and new AMA CPT codes for their devices effective January 2024. Patient treatments increased to over 47,000 worldwide, with more than 2,000 trained dentists. The company projects achieving positive cash flow from operations by mid-2025.
Vivos Therapeutics (NASDAQ: VVOS), a medical device company focused on sleep-related breathing disorders treatment, announced its plans to release Q3 2024 financial results after market close on November 14, 2024. The company will host a conference call at 5:00 PM ET on the same day to discuss results and recent developments. Investors can access the call via phone at (800) 717-1738 (US) or (646) 307-1865 (International). A replay will be available until November 29, 2024, and a live webcast can be accessed through the company's website.
Vivos Therapeutics (NASDAQ: VVOS) has announced that the American Medical Association (AMA) has issued new CPT® medical codes for all Vivos CARE oral medical devices, effective January 1, 2025. This development is expected to facilitate coverage and reimbursement by commercial medical insurance payers for the treatment of obstructive sleep apnea (OSA) in adults and children.
Vivos Chairman and CEO, Kirk Huntsman, stated that this approval will enable a larger number of patients to access their proprietary airway remodeling technology. The company believes this, along with recent regulatory approvals and their new alliance-based marketing and distribution model, will improve their position to drive revenue growth.
The AMA's CPT® 2025 code set includes 420 overall updates, with 270 new codes, 112 deletions, and 38 revisions. This approval follows Vivos' recent Medicare coverage approval and is seen as a major step towards making OSA treatment more accessible and affordable for patients nationwide, including children ages 6 to 17.
Vivos Therapeutics (NASDAQ: VVOS), a medical device company specializing in sleep-related breathing disorders treatments, has announced a $4.3 million registered direct offering of common stock. The offering involves the sale of 1,363,812 shares at $3.15 per share, priced at-the-market under Nasdaq rules. No warrants are being issued. The offering is expected to close around September 20, 2024, with H.C. Wainwright & Co. acting as the exclusive placement agent. Vivos intends to use the net proceeds for working capital and general corporate purposes. The offering is made pursuant to a previously filed and effective shelf registration statement.
